Search
Efinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalIt was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.
Poa pratensis pollen
go.drugbank.com/drugs/DB10366ApprovedPoa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.
Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen MixAmiodarone
go.drugbank.com/drugs/DB01118ApprovedInvestigationalAmiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpat...
Everolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalEverolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a simi...
Hexamethonium
go.drugbank.com/drugs/DB08960ExperimentalIt has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalIt was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalHexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®.
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.
Probenecid
go.drugbank.com/drugs/DB01032ApprovedInvestigationalThe prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubu...